Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review

Obradovic, Jasmina; Todosijević, Jovana; Jurišić, Vladimir

doi:10.1007/s11033-021-06379-w

Cited by 17 publications

(7 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Smoking promotes the progression of cancer cells and reduces the sensitivity of NSCLC cells to EGFR-TKIs through the liver kinase B1/AMP-activated protein kinase (LKB1/AMPK) pathway, promoting Src (Y527F/K295R), epithelial-mesenchymal transition (EMT), and ROS, as well as abnormal EGF receptor activation. 20-24 Previous research works also suggest that nicotine in tobacco can mediate resistance to EGFR-TKIs in NSCLC patients with EGFR mutations. 25 Therefore, we believe that smoking may affect the efficacy of EGFR-TKI by altering the expression of driving genes in NSCLC patients and mediating EGFR-TKIs resistance.…”

Section: Discussionmentioning

confidence: 99%

“…The methods used in testing EGFR variants for NSCLC patients were mostly polymerase chain reaction (PCR) and sequencing, which have been proved to be sensitive and specific for EGFR variants detection and indicated that our study was reliable. 18 The impact of EGFR-TKIs alone or EGFR-TKIs combined with other treatments in 6760 patients for advanced NSCLC with different smoking habits was evaluated. Progressive-free survival was evaluated in 4301 patients, and OS was evaluated in 6229 patients, with reliable results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis

Mo,

Ye,

et al. 2023

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered as the first-line treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to analyze the efficacy of EGFR-TKIs treatment in patients with advanced NSCLC of different smoking habits. Methods: We conducted a search for meta-analyses and systematic reviews on the PubMed, MEDLINE, Embase, and the Cochrane Library to address this knowledge gap. Patients were divided into 2 groups: (1) experimental group: treated with EGFR-TKIs or EGFR-TKIs combined with chemotherapy, immunotherapy, antiangiogenesis, radiotherapy and (2) control group: treated with chemotherapy. Progressive-free survival (PFS) and total survival (OS) were adopted for evaluating the efficacy of EGFR-TKIs between experimental group and control group. Results: Eleven studies including 6760 patients were included in the meta-analysis. The results showed that smoking (including previous and current smoking) significantly reduces the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs. In addition, EGFR-TKIs combined with anti-vascular endothelial growth factor therapy can reduce the risk of disease progression in smokers. Conclusions: Our study indicated that smoking significantly reduced the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis

Mo,

Ye,

et al. 2023

Clin Med Insights Oncol

View full text Add to dashboard Cite

show abstract

“…The present study also suggests several problems to solve in the CGP process, including sample quality and the management of PGPVs. Generally, the performance of diagnostic tests can be influenced by the method, region, and time period [36]. Although FoudationOne ® CDx centralizes testing to maintain quality, it's important to acknowledge that pre-analytical factors can impact testing success [37].…”

Section: Discussionmentioning

confidence: 99%

Homologous Recombination Repair Gene Alterations Are Associated with Tumor Mutational Burden and Survival of Immunotherapy

Ito,

Kubo,

Kawaji

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Comprehensive genomic profiling (CGP) has become generally accepted practice in cancer care since CGP has become reimbursed by national healthcare insurance in Japan in 2019. However, its usefulness for cancer patients is insufficient for several reasons. Methods: In an observational clinical study of FoundationOne® CDx, potential biomarkers were explored and the cause of testing failure was investigated. A total of 220 cancer patients were enrolled in the study during the period from 2018 to 2019 at Kyushu University Hospital. Results: The primary tumor sites of the 220 cases were breast (115), colon (29), stomach (19), and pancreas (20). The present dataset suggested that homologous recombination repair (HRR) gene alterations were positively associated with tumor mutational burden-high (TMB-high) (p = 0.0099). A public dataset confirmed that patients with HRR gene alterations had a higher TMB and showed significantly longer survival of immunotherapy. In the present study, 18 cases failed sequencing. A lower percentage of tumor cell nuclei was the most common reason for testing failures (p = 0.037). Cases that received neoadjuvant chemotherapy before sampling tended to fail testing. Conclusions: HRR gene alterations can be a potential biomarker predicting TMB-high and a good response to immunotherapy. For successful sequencing, samples with lower percentages of tumor cell nuclei and previous neoadjuvant chemotherapy should be avoided.

show abstract

“…One of the recommended NAAT techniques for Covid-19 detection was reverse transcriptionquantitative PCR (RT-PCR) [5]. The major advantage of the PCR methods is the applicability to different areas of research after the proper assay optimization [13,14].…”

Section: Sensitivity and Specificity Of The Polymerase Chain Reactionmentioning

confidence: 99%

Sensitivity and Specificity of the Assays in the Covid-19 Pandemic

Obradovic¹,

Jurišić²

2022

RAP Conference Proceedings

View full text Add to dashboard Cite

Quick identification of coronavirus was an emergency in the COVID-19 pandemic. The most used diagnostic tools were serologic, rapid antigen tests, as fast, easily applicable, and affordable, but with lower sensitivity. The results were usually confirmed with a reverse transcription polymerase chain reaction. This assay requires proper expertise and robust laboratory equipment. It is further, costly and time-consuming, with restricted application in low-income countries. Even so, it is used as a golden standard, since it has high specificity and sensitivity. The serologic antibodybased assays were also applied during this Covid-19 burden. Their application was able two weeks after the Covid-19 onset since that was the period when antibodies might be detected. Here are briefly presented the advantages and disadvantages of these assays. Meanwhile, the majority of the diagnostic tests were developed, with some of them being automated and highly sensitive, but often costly. The general recommendation is the improvement of the sensitivity of the serologic tests and development of the easily applicable, fast, and accurate diagnostic tests.

show abstract

Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review

Cited by 17 publications

References 90 publications

Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis

Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis

Homologous Recombination Repair Gene Alterations Are Associated with Tumor Mutational Burden and Survival of Immunotherapy

Sensitivity and Specificity of the Assays in the Covid-19 Pandemic

Contact Info

Product

Resources

About